Tesamorelin 10mg · GHRH Analog · Research Peptide

Compound Profile

Researcher-grade specs. No guesswork.

Each vial ships with the structural data and lot identifiers researchers need for traceable, reproducible work.

Built for the bench.

Synthesized via solid-phase peptide chemistry, purified by reverse-phase HPLC, verified by mass spectrometry, and tested for sterility and endotoxin load. Every spec below is documented on the signed Certificate of Analysis that ships with your vial.

View signed COA

Compound

Tesamorelin

Class

GHRH analog (44-AA)

Sequence

trans-3-hexenoyl-hGRF(1-44)-NH₂

CAS Number

901758-09-6

Molecular Formula

C₂₂₁H₃₆₆N₇₂O₆₇S

Molecular Weight

5135.84 g/mol

Concentration

10 mg / vial

Form

White powder

Purity (HPLC)

≥ 99%

Identity (LC-MS)

Confirmed

Storage

2-8°C, sealed, dry

Origin

Made in the USA

In the Literature

What researchers are studying.

A short, sourced summary of where Tesamorelin appears in the published research record. For context only. Not a claim, not a protocol, not advice.

Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH). The N-terminus carries a stabilizing trans-3-hexenoyl modification that resists enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), extending its functional half-life relative to native GHRH(1-44).

Tesamorelin is notable as the only GHRH-analog peptide approved by the FDA for any indication — originally for the reduction of excess abdominal fat in HIV-associated lipodystrophy under the brand name Egrifta (Theratechnologies). Outside that approved use, the compound remains a research compound.

In the published preclinical and clinical literature, Tesamorelin is most-cited alongside investigations of the GH/IGF-1 axis, visceral adipose tissue biology, hepatic fat metabolism, lipid profile modulation, and pulsatile somatotropic signaling. Use outside the approved indication has not been evaluated by the FDA.

For research use only. Statements above describe published research literature and do not constitute health, medical, or therapeutic claims. Not for human or veterinary use. Not evaluated by the FDA.

Documented Research Areas

GHRH analog pharmacology and DPP-IV resistance
GH/IGF-1 axis stimulation and pulsatile release
Visceral adipose tissue biology (clinical)
Hepatic fat and non-alcoholic fatty liver research
Lipid profile and metabolic marker studies
HIV-associated lipodystrophy (FDA-approved indication)

Selected Studies · Peer-Reviewed Literature

A curated list of published peer-reviewed papers indexed in PubMed where Tesamorelin has been studied. Provided for research-context only. Linking to the literature does not constitute endorsement of any therapeutic application.

Falutz J, et al. (2007) · N Engl J Med Metabolic effects of a growth hormone-releasing factor in patients with HIV PubMed · 18046029
Stanley TL, et al. (2014) · JAMA Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation PubMed · 25027142
Stanley TL, et al. (2019) · Lancet HIV Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial PubMed · 31303465
Falutz J, et al. (2010) · J Acquir Immune Defic Syndr Long-term safety and effects of tesamorelin, a GHRH analogue, in HIV patients with abdominal fat accumulation PubMed · 20431394
Spooner LM, Olin JL. (2012) · Ann Pharmacother Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy PubMed · 22318927
Adrian S, et al. (2018) · J Clin Endocrinol Metab The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV PubMed · 30032213
Clemmons DR, et al. (2017) · J Clin Endocrinol Metab Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes PubMed · 28323959
Falutz J, et al. (2008) · J Clin Endocrinol Metab A tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials PubMed · 20484485

Transparency

Every lot. Every researcher. Same proof.

Each batch ships with a third-party Certificate of Analysis from BioRegen Analytical. HPLC purity, mass-spectrometry identity, sterility, and LAL endotoxin screening. Every test, every lot.

Your lot number ships on the label and on the COA. Enter it in the verifier any time to retrieve the original lab report.

Verify Your Batch Download Sample COA

Certificate of Analysis

BioRegen Analytical · Independent Lab · Lot #11653

CompoundTesamorelin

CAS#901758-09-6

FormulaC₂₂₁H₃₆₆N₇₂O₆₇S

Mol. Weight5135.84 g/mol

Identity (LC-MS)PASS · 710.36 m/z

Purity (HPLC)99.72%

Retention Time3.68 min

Sterility / LALPASS

Date Tested2026-04-12

Sample · Live data on verifier

Pairs With

Related compounds.

Other research peptides in the Elixser catalog cited alongside Tesamorelin in the published research literature.

Stack

Tesa + Ipa

5mg / 5mg blend

GHRH analog plus selective GH secretagogue, two complementary points on the somatotrophic axis.

Mod GRF (1-29) plus selective GH secretagogue, paired in published GH-axis research.

10mg · mitochondrial-derived

Mitochondrial-derived peptide cited in metabolic and AMPK signaling research.

$60

View →

Common Questions

Answered straight.

Native human GHRH(1-44) is rapidly degraded by the enzyme dipeptidyl peptidase-IV (DPP-IV), which cleaves it within minutes of release into circulation. Tesamorelin adds a trans-3-hexenoyl group at the N-terminus, blocking DPP-IV cleavage and extending the functional half-life of the peptide. The amino acid sequence remains otherwise identical to native GHRH — Tesamorelin acts on the same GHRH receptor with the same downstream pharmacology.

Tesamorelin is the only GHRH-analog peptide approved by the FDA for any indication — originally for the reduction of excess abdominal fat in HIV-associated lipodystrophy, marketed under the brand name Egrifta. That approval applies only to the specific clinical indication. This Elixser product is research-grade material intended for laboratory research only — not the FDA-approved drug product, not for human use, and not for any indication outside the original research context.

Every lot is tested by reverse-phase HPLC and certified at ≥99% purity. The Certificate of Analysis lists the exact lot purity (most lots run between 99.5% and 99.9%). Your COA ships with the vial and is also retrievable by lot number through our online verifier.

Testing is done by BioRegen Analytical, an independent third-party lab. Every batch goes through HPLC purity, LC-MS identity confirmation, sterility screening, and LAL endotoxin testing. The signed Certificate of Analysis ships with each vial. Same lot number, same COA, every time.

Made in the USA. Synthesized in a US cGMP-aligned facility. Tested by a US-based independent lab. Shipped from US fulfillment.

Orders ship via 2-day expedited delivery from US fulfillment. Free over $150. Vials are sealed, packaged with insulation, and shipped in tamper-evident packaging. Tracking number is sent the same day your order leaves the warehouse.

30-day money-back guarantee on every order. If a vial arrives damaged, fails to match the COA, or you change your mind within 30 days, contact us and we will refund or replace. No restocking fees, no return shipping cost on defective product.

One sealed 10mg vial of Tesamorelin as a white powder. Lot-stamped label. Signed Certificate of Analysis. Tamper-evident packaging. Bacteriostatic water for reconstitution research is sold separately and can be added in the cart.

Store sealed at 2-8°C, away from direct light, heat, and moisture. Sealed shelf life is 24 months from the date on the COA. Once reconstituted for research, store reconstituted material refrigerated and follow standard peptide-handling protocols for your lab.

No. All Elixser Peptides products are sold strictly for laboratory research and in vitro study. They are not drugs, food, or cosmetics. They are not for human or veterinary use, consumption, or therapeutic application. They have not been evaluated by the FDA. By purchasing, you agree to use these materials in compliance with applicable laws and ethical research standards.

Research Use Only

Tesamorelin

Researcher-grade specs. No guesswork.

Built for the bench.

What researchers are studying.

Every lot. Every researcher. Same proof.

Related compounds.

Answered straight.

Add Tesamorelin 10mg to your research arsenal.